Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

Largest group on African continent introduced to Sign Language
2016-07-05

Description: z UFS101 SASL Tags: z UFS101 SASL

The introduction of basic Sign Language
as part of the UFS101 course was a great
success. From left are Susan Lombaard,
Annemarie le Roux, Tshisikhawe Dzivhani
(all from the Department of South African
Sign Language), and Lauren Oosthuizen
(UFS101).

Photo: Leonie Bolleurs

As a result of a new initiative at the University of the Free State (UFS), the largest group of students on the African continent took part in a first-year seminar which included Sign Language.

A total of 5400 students on the Bloemfontein Campus and 1000 on Qwaqwa Campus were taught basic Sign Language by Susan Lombaard, Acting Head of the Department of South African Sign Language, and her team members, Tshisikhawe Dzivhani, Annemarie le Roux, and Nicolene de Klerk.

It forms part of the UFS101 module presented to all first-year students. The initiative, begun in the first semester of 2016, will form part of UFS101 in future and was met with an overwhelmingly positive response.

Three segments of course

Sign Language was taught in three segments and positioned as large-class learning experiences in the Callie Human Centre (Bloemfontein Campus) and the Nelson Mandela Hall (Qwaqwa Campus). Students were taught about deaf culture, Sign Language theory, as well as how to sign their names, exchange pleasantries, and have a basic conversation.

A valuable skill to have

“It (the Sign Language experience) was very interesting and helpful,” said one of the students. “It is important to have the ability to communicate with all sorts of people, and to be able to help them in a crisis”. According to another, it sparked an interest in Sign Language. “It is a skill I will continue to use and try to learn more from it,” said a third.

Lombaard – in collaboration with the UFS101 team – will be presenting a paper related to this achievement at the DeafNet Africa Conference in Johannesburg, from 26 to 30 September 2016.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept